Atorvastatin-Medicated Dentifrice Significantly Inhibits CD4+ T Cell Proliferation: In vitro Pilot Study

Reports indicate that statins (cholesterol-lowering drugs), in addition to lowering cholesterol, have an immunomodulatory effect. This effect may be beneficial for the treatment of several diseases, including periodontal disease. The aim of the present study was to evaluate the immunomodulatory effe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rosenberg,David R, Kernitsky,Jeremy R, Andrade,Catherine X, Ramirez,Valeria, Violant,Deborah, Nart,José
Lenguaje:	English
Publicado:	Sociedad Chilena de Anatomía 2017
Materias:	Atorvastatin calcium Dentifrices T cells Flow cytometry
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-95022017000200002
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0717-95022017000200002
record_format	dspace
spelling	oai:scielo:S0717-950220170002000022017-08-07Atorvastatin-Medicated Dentifrice Significantly Inhibits CD4+ T Cell Proliferation: In vitro Pilot StudyRosenberg,David RKernitsky,Jeremy RAndrade,Catherine XRamirez,ValeriaViolant,DeborahNart,José Atorvastatin calcium Dentifrices T cells Flow cytometry Reports indicate that statins (cholesterol-lowering drugs), in addition to lowering cholesterol, have an immunomodulatory effect. This effect may be beneficial for the treatment of several diseases, including periodontal disease. The aim of the present study was to evaluate the immunomodulatory effect of an atorvastatin-medicated dentifrice on CD4+ T cell proliferation. CD4+ T cell proliferation assays and peripheral blood mononuclear cell (PBMC) viability assays were conducted on PBMCs from healthy donors cultured under the following conditions: control, atorvastatin solution, atorvastatin-medicated dentifrice, and dentifrice without atorvastatin at concentrations of 1, 5, 10, 50 and 100 µM. A Generalized Equation Estimation (GEE) model was used to analyze concentration versus proliferation and concentration versus percentage of dead cells within each group evaluated. Atorvastatin-medicated dentifrice (p-value <0.0001) and atorvastatin solution (p-value <0.0001) significantly inhibited CD4+ T cell proliferation in a dose-dependent manner compared with the dentifrice without atorvastatin and control conditions. Only the relationship between atorvastatin solution and percentage of dead cells was significant compared to the other conditions (p-value 0.019). The results revealed that atorvastatin-medicated dentifrice at concentrations of 1 to 100 µM had immunomodulatory effects, inhibiting CD4+ T cell proliferation without affecting PBMC viability. The other components of the dentifrice did not affect CD4+ T cell proliferation or cell viability, indicating its utility as a vehicle to achieve the desired effects of atorvastatin in periodontal tissue. Controlled clinical trials are still needed to evaluate the clinical effects of an atorvastatin-medicated dentifrice on the periodontium.info:eu-repo/semantics/openAccessSociedad Chilena de AnatomíaInternational Journal of Morphology v.35 n.2 20172017-06-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-95022017000200002en10.4067/S0717-95022017000200002
institution	Scielo Chile
collection	Scielo Chile
language	English
topic	Atorvastatin calcium Dentifrices T cells Flow cytometry
spellingShingle	Atorvastatin calcium Dentifrices T cells Flow cytometry Rosenberg,David R Kernitsky,Jeremy R Andrade,Catherine X Ramirez,Valeria Violant,Deborah Nart,José Atorvastatin-Medicated Dentifrice Significantly Inhibits CD4+ T Cell Proliferation: In vitro Pilot Study
description	Reports indicate that statins (cholesterol-lowering drugs), in addition to lowering cholesterol, have an immunomodulatory effect. This effect may be beneficial for the treatment of several diseases, including periodontal disease. The aim of the present study was to evaluate the immunomodulatory effect of an atorvastatin-medicated dentifrice on CD4+ T cell proliferation. CD4+ T cell proliferation assays and peripheral blood mononuclear cell (PBMC) viability assays were conducted on PBMCs from healthy donors cultured under the following conditions: control, atorvastatin solution, atorvastatin-medicated dentifrice, and dentifrice without atorvastatin at concentrations of 1, 5, 10, 50 and 100 µM. A Generalized Equation Estimation (GEE) model was used to analyze concentration versus proliferation and concentration versus percentage of dead cells within each group evaluated. Atorvastatin-medicated dentifrice (p-value <0.0001) and atorvastatin solution (p-value <0.0001) significantly inhibited CD4+ T cell proliferation in a dose-dependent manner compared with the dentifrice without atorvastatin and control conditions. Only the relationship between atorvastatin solution and percentage of dead cells was significant compared to the other conditions (p-value 0.019). The results revealed that atorvastatin-medicated dentifrice at concentrations of 1 to 100 µM had immunomodulatory effects, inhibiting CD4+ T cell proliferation without affecting PBMC viability. The other components of the dentifrice did not affect CD4+ T cell proliferation or cell viability, indicating its utility as a vehicle to achieve the desired effects of atorvastatin in periodontal tissue. Controlled clinical trials are still needed to evaluate the clinical effects of an atorvastatin-medicated dentifrice on the periodontium.
author	Rosenberg,David R Kernitsky,Jeremy R Andrade,Catherine X Ramirez,Valeria Violant,Deborah Nart,José
author_facet	Rosenberg,David R Kernitsky,Jeremy R Andrade,Catherine X Ramirez,Valeria Violant,Deborah Nart,José
author_sort	Rosenberg,David R
title	Atorvastatin-Medicated Dentifrice Significantly Inhibits CD4+ T Cell Proliferation: In vitro Pilot Study
title_short	Atorvastatin-Medicated Dentifrice Significantly Inhibits CD4+ T Cell Proliferation: In vitro Pilot Study
title_full	Atorvastatin-Medicated Dentifrice Significantly Inhibits CD4+ T Cell Proliferation: In vitro Pilot Study
title_fullStr	Atorvastatin-Medicated Dentifrice Significantly Inhibits CD4+ T Cell Proliferation: In vitro Pilot Study
title_full_unstemmed	Atorvastatin-Medicated Dentifrice Significantly Inhibits CD4+ T Cell Proliferation: In vitro Pilot Study
title_sort	atorvastatin-medicated dentifrice significantly inhibits cd4+ t cell proliferation: in vitro pilot study
publisher	Sociedad Chilena de Anatomía
publishDate	2017
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-95022017000200002
work_keys_str_mv	AT rosenbergdavidr atorvastatinmedicateddentifricesignificantlyinhibitscd4tcellproliferationinvitropilotstudy AT kernitskyjeremyr atorvastatinmedicateddentifricesignificantlyinhibitscd4tcellproliferationinvitropilotstudy AT andradecatherinex atorvastatinmedicateddentifricesignificantlyinhibitscd4tcellproliferationinvitropilotstudy AT ramirezvaleria atorvastatinmedicateddentifricesignificantlyinhibitscd4tcellproliferationinvitropilotstudy AT violantdeborah atorvastatinmedicateddentifricesignificantlyinhibitscd4tcellproliferationinvitropilotstudy AT nartjose atorvastatinmedicateddentifricesignificantlyinhibitscd4tcellproliferationinvitropilotstudy
_version_	1718444998644465664

Atorvastatin-Medicated Dentifrice Significantly Inhibits CD4+ T Cell Proliferation: In vitro Pilot Study

Ejemplares similares